These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 22924551)

  • 1. Modeling androgen receptor flexibility: a binding mode hypothesis of CYP17 inhibitors/antiandrogens for prostate cancer therapy.
    Gianti E; Zauhar RJ
    J Chem Inf Model; 2012 Oct; 52(10):2670-83. PubMed ID: 22924551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
    Handratta VD; Vasaitis TS; Njar VC; Gediya LK; Kataria R; Chopra P; Newman D; Farquhar R; Guo Z; Qiu Y; Brodie AM
    J Med Chem; 2005 Apr; 48(8):2972-84. PubMed ID: 15828836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
    Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
    Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of novel androgen receptor antagonists using structure- and ligand-based methods.
    Li H; Ren X; Leblanc E; Frewin K; Rennie PS; Cherkasov A
    J Chem Inf Model; 2013 Jan; 53(1):123-30. PubMed ID: 23278403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.
    Vasaitis T; Belosay A; Schayowitz A; Khandelwal A; Chopra P; Gediya LK; Guo Z; Fang HB; Njar VC; Brodie AM
    Mol Cancer Ther; 2008 Aug; 7(8):2348-57. PubMed ID: 18723482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001.
    DeVore NM; Scott EE
    Nature; 2012 Jan; 482(7383):116-9. PubMed ID: 22266943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
    Njar VC; Brodie AM
    J Med Chem; 2015 Mar; 58(5):2077-87. PubMed ID: 25591066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Learning from estrogen receptor antagonism: structure-based identification of novel antiandrogens effective against multiple clinically relevant androgen receptor mutants.
    Liu B; Geng G; Lin R; Ren C; Wu JH
    Chem Biol Drug Des; 2012 Mar; 79(3):300-12. PubMed ID: 22151347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of novel steroidal imidazoles as dual inhibitors of AR/CYP17 for the treatment of prostate cancer.
    Hou Q; He C; Lao K; Luo G; You Q; Xiang H
    Steroids; 2019 Oct; 150():108384. PubMed ID: 30885648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting CYP17: established and novel approaches in prostate cancer.
    Yap TA; Carden CP; Attard G; de Bono JS
    Curr Opin Pharmacol; 2008 Aug; 8(4):449-57. PubMed ID: 18619560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel androgen receptor antagonists: a hybrid approach of pharmacophore-based and docking-based virtual screening.
    Liu J; Liu B; Guo G; Jing Y; Zhao G
    Anticancer Drugs; 2015 Aug; 26(7):747-53. PubMed ID: 25933245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells.
    Soifer HS; Souleimanian N; Wu S; Voskresenskiy AM; Collak FK; Cinar B; Stein CA
    J Biol Chem; 2012 Feb; 287(6):3777-87. PubMed ID: 22174412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity.
    Tamura H; Yoshioka M; Hasegawa M; Hosoda A; Matsugi M; Akamatsu M
    Bioorg Med Chem; 2013 Jun; 21(11):2968-74. PubMed ID: 23611768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined Ligand/Structure-Based Virtual Screening and Molecular Dynamics Simulations of Steroidal Androgen Receptor Antagonists.
    Wang Y; Han R; Zhang H; Liu H; Li J; Liu H; Gramatica P
    Biomed Res Int; 2017; 2017():3572394. PubMed ID: 28293633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer.
    Norris JD; Ellison SJ; Baker JG; Stagg DB; Wardell SE; Park S; Alley HM; Baldi RM; Yllanes A; Andreano KJ; Stice JP; Lawrence SA; Eisner JR; Price DK; Moore WR; Figg WD; McDonnell DP
    J Clin Invest; 2017 Jun; 127(6):2326-2338. PubMed ID: 28463227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP17 inhibitors for prostate cancer therapy.
    Vasaitis TS; Bruno RD; Njar VC
    J Steroid Biochem Mol Biol; 2011 May; 125(1-2):23-31. PubMed ID: 21092758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational prediction of new CYP17 inhibitors based on pharmacophore modeling, virtual screening and docking approach.
    Haidar S; Hartmann RW
    Pharmazie; 2017 Sep; 72(9):529-536. PubMed ID: 29441980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists.
    Guo C; Pairish M; Linton A; Kephart S; Ornelas M; Nagata A; Burke B; Dong L; Engebretsen J; Fanjul AN
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2572-8. PubMed ID: 22377517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer.
    Mohler ML; Sikdar A; Ponnusamy S; Hwang DJ; He Y; Miller DD; Narayanan R
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational design of novel antiandrogens for neutralizing androgen receptor function in hormone refractory prostate cancer.
    Singh P; Hallur G; Anchoori RK; Bakare O; Kageyama Y; Khan SR; Isaacs JT
    Prostate; 2008 Oct; 68(14):1570-81. PubMed ID: 18668523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.